{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:48:03Z","timestamp":1778917683260,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,10,24]],"date-time":"2008-10-24T00:00:00Z","timestamp":1224806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2009,1,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mouse units used to quantify the activity of botulinum A toxin preparations are not equivalent and issues concerning efficacy and safety remain with regard to their respective potencies and diffusion qualities in human tissue. We compared the effects of Botox\u00ae (BOT) and Dysport\u00ae (DYS) in different doses and dilutions in a human skin model. Eighteen (8 women, 10 men) healthy volunteers, aged 28.4 years \u00b1 5.7 years were injected intradermally with pure saline, BOT and DYS at 16 points in the abdomen in random order and in a double\u2010blind condition, using two conversion ratios (1:3 and 1:4) and three different dilution schemes. For an objective outcome, the Ninhydrin sweat test was used to compare the anhidrotic areas. Both preparations showed a linear dose and dilution relationship with similar variances of responses for anhidrosis and hypohidrosis, indicating the same reliability of response. The dose equivalence conversion ratios (BOT: DYS) were 1:1.3 for anhidrosis and 1:1.6 for hypohidrosis (1:1.1\u20101.5 and 1:1.4\u20101.8 95% confidence intervals). The diffusion characteristics of both products were similar. A dose equivalence factor of more than 1:2 (BOT:DYS) is not supported by these objective and reproducible data. \u00a9 2008 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.22336","type":"journal-article","created":{"date-parts":[[2008,10,24]],"date-time":"2008-10-24T15:22:16Z","timestamp":1224861736000},"page":"231-236","source":"Crossref","is-referenced-by-count":42,"title":["Respective potencies of Botox\u00ae and Dysport\u00ae in a human skin model: A randomized, double\u2010blind study"],"prefix":"10.1002","volume":"24","author":[{"given":"Gottfried","family":"Kranz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Haubenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Voller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Posch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schnider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Auff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Sycha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,10,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2001.00035.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01439.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104253241707"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20066"},{"key":"e_1_2_6_6_2","first-page":"231","article-title":"Dose standardization of botulinum toxin","volume":"78","author":"Van den Bergh PY","year":"1998","journal-title":"Adv Neurol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.11.009"},{"key":"e_1_2_6_8_2","first-page":"459","article-title":"Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia","volume":"72","author":"Ranoux D","year":"2002","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120627"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20468"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01438.x"},{"key":"e_1_2_6_12_2","first-page":"493","article-title":"Botulinum toxin: dangerous terminology errors","volume":"86","author":"Brin MF","year":"1993","journal-title":"J R Soc Med"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20073"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000287087.99612.e5"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.40B3.454"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04349.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X36396"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2003.08.001"},{"key":"e_1_2_6_19_2","first-page":"719","article-title":"Potency equivalence of botulinum toxin preparations","volume":"87","author":"Hambleton P","year":"1994","journal-title":"J R Soc Med"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1006\/taap.1994.1181"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.1999.tb00032.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-0101(01)00101-5"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01446.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00941758"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.1.6"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.1998.520181.x"},{"key":"e_1_2_6_27_2","unstructured":"WohlfarthK WegnerF SchwandtI et al.Pharmacokinetic properties of different preparations of botulinum neurotoxin type a. In: Poster presented at the 5th international conference on basic and therapeutic aspects of botulinum and tetanus toxins Denver Colorado June 23\u201325 2005."}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22336","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.22336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:59:42Z","timestamp":1760957982000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.22336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,24]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,1,30]]}},"alternative-id":["10.1002\/mds.22336"],"URL":"https:\/\/doi.org\/10.1002\/mds.22336","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,24]]}}}